<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836809</url>
  </required_header>
  <id_info>
    <org_study_id>HM15024</org_study_id>
    <nct_id>NCT01836809</nct_id>
  </id_info>
  <brief_title>Nesiritide and Renal Function After the Total Artificial Heart</brief_title>
  <official_title>The Impact of Nesiritide on Renal Function After Implantation of the Total Artificial Heart and Left Ventricular Assist Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of renal dysfunction after implantation of the artificial heart is high. The
      infusion of exogenous B-type natriuretic peptide (BNP) after implantation of the total
      artificial heart (TAH) improves renal function in a sustained manner. The renal protective
      and hormone-modulating effects of nesiritide may be enhanced with ventriculectomy compared to
      heart failure surgery that leaves the native myocardium intact. The goal of this project is
      to determine the renal protective effects of nesiritide after implantation of a mechanical
      device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blinded placebo controlled study that will take place in the
      Cardiac Surgery Intensive Care Unit, at Virginia Commonwealth University (VCU) Hospital
      Center.

      This study will enroll 20 adult patients who have undergone implantation of a circulatory
      support device (10 TAH patients, 10 Left ventricular assist device (LVAD) patients). Patients
      will receive standard postoperative care, including anticoagulation, continuous hemodynamic
      monitoring with an arterial line and central venous line and hemodynamic support as determine
      by the cardiac surgery clinical team. We will exclude patients who are receiving renal
      replacement therapy at the time of device implantation or those that have had previous solid
      organ transplantation in order to remove the confounding influence of calcineurin inhibitor
      exposure on renal function. Patient unable to provide informed consent will also be excluded.

      Nesiritide Infusion

      The patients will be randomized (stratified by device type) to either the study drug
      (nesiritide at 0.005 mcg/kg/min without a bolus) or placebo. A fixed-dose infusion will be
      initiated 6 hours after the patients having come off of cardiopulmonary bypass and continued
      for 48 hours.

      Laboratory Measurements

      Acute and chronic effects of nesiritide on Glomerular Filtration Rate (GFR) and Renal Plasma
      Flow (RPF) will be measured by continuous infusion of iothalamate (IOTH) and phenylalanine
      hydroxylase (PAH), respectively. GFR and RPF will be measured at baseline (-3 to 0 hrs) and
      at 3 intervals during drug/placebo administration as follows: 0 to 6, 6 to 16 and 16 to 40.
      Intravenous catheters will be placed as needed for infusion of PAH and IOTH and for timed
      blood collections.

      Urine volume, creatinine, sodium excretion will also be measured. Neurohormones will be
      measured at all time points 3-6. Plasma renin activity will be measured with an automated
      chemiluminescent immunoassay (DiaSorin Liaison). Serum aldosterone concentration will be
      determined by liquid chromatography-mass spectrometry (Agilent, AB Sciex API 5000). Serum BNP
      concentration will be measured with a sandwich chemiluminescent immunoassay (Siemens
      Healthcare Diagnostics, ADVIA Centaur BNP immunoassay).

      Statistical Analysis Sample size was determined using urine output data from our preliminary
      observations. Power calculations showed that a total of 10 patients in this two-treatment
      parallel-design study to have 84 percent power to detect a change in urine output by 75 mL/hr
      at a two-sided 0.05 significance level (using standard deviation of 35 mL/hr for urine
      output). Thus 10 patient were included in each device arm of the study.Chi-square analysis
      was used to compare discrete variables.

      A two tailed Student's t-test was used to compare continuous variables. A repeated measures
      analysis of variance (ANOVA) was used to compare changes in clinical variables laboratory
      measurements across time points. A P value &lt; 0.05 was considered significant. For individual
      comparisons post-hoc testing was performed with a paired t-test analysis with Bonferroni
      correction for 2 comparisons and thus only a P value &lt; 0.025 will considered significant for
      the repeated measures analyses. A Student 2-tailed paired t test will be used to compare
      placebo and active drug values for each individual time point.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility for enrollment
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular Filtration Rate</measure>
    <time_frame>46 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Plasma Flow</measure>
    <time_frame>46 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Hemodialysis/Renal Replacement Therapy</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Output</measure>
    <time_frame>46 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Renal Failure</measure>
    <time_frame>46 Hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Diuretic Requirement</measure>
    <time_frame>46 Hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Cardiorenal Syndrome</condition>
  <arm_group>
    <arm_group_label>Total Artificial Heart</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nesiritide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Artificial Heart: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LVAD: Nesiritide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active arm of the LVAD group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LVAD: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control arm for subjects receiving LVAD and randomized to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nesiritide</intervention_name>
    <description>nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
    <arm_group_label>Total Artificial Heart</arm_group_label>
    <arm_group_label>LVAD: Nesiritide</arm_group_label>
    <other_name>Natrecor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
    <arm_group_label>Total Artificial Heart: Placebo</arm_group_label>
    <arm_group_label>LVAD: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Implanted with a total artificial heart (CardioWest) or Left ventricular assist device
             (HeartMate II)

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  Previous calcineurin inhibitor (CNI) exposure

          -  Hemodialysis prior to device implant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keyur B. Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2013</study_first_posted>
  <results_first_submitted>July 7, 2014</results_first_submitted>
  <results_first_submitted_qc>August 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2014</results_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Artificial Heart</keyword>
  <keyword>Left Ventricular Assist Device</keyword>
  <keyword>Natriuretic peptides</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiorenal Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Total Artificial Heart</title>
          <description>Active arm of Total Artificial Heart group
randomized to receive nesiritide at 0.005 mcg/kg/min without a bolus</description>
        </group>
        <group group_id="P2">
          <title>Total Artificial Heart: Placebo</title>
          <description>This arm included subject who received a total artificial heart and will be randomized receive placebo</description>
        </group>
        <group group_id="P3">
          <title>LVAD: Nesiritide</title>
          <description>Active arm of the LVAD group
randomized to receive nesiritide at 0.005 mcg/kg/min without a bolus</description>
        </group>
        <group group_id="P4">
          <title>LVAD: Placebo</title>
          <description>This arm will consist of subjects who received an LVAD and will be randomized to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Artificial Heart</title>
          <description>Active arm of the Total Artificial Heart group
randomized to nesiritide</description>
        </group>
        <group group_id="B2">
          <title>Total Artificial Heart: Placebo</title>
          <description>Total Artificial Heart group
randomized to placebo</description>
        </group>
        <group group_id="B3">
          <title>LVAD: Nesiritide</title>
          <description>Active arm of the LVAD group
randomized to nesiritide</description>
        </group>
        <group group_id="B4">
          <title>LVAD: Placebo</title>
          <description>Control arm of the LVAD group
randomized to placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="59.5" lower_limit="58" upper_limit="61"/>
                    <measurement group_id="B5" value="59.5" lower_limit="58" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glomerular Filtration Rate</title>
        <time_frame>46 hours</time_frame>
        <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
        <group_list>
          <group group_id="O1">
            <title>Total Artificial Heart</title>
            <description>Active arm of the Total Artificial Heart group
randomized to receive nesiritide</description>
          </group>
          <group group_id="O2">
            <title>Total Artificial Heart: Placebo</title>
            <description>Control arm of the Total Artificial Heart group
randomized to receive placebo</description>
          </group>
          <group group_id="O3">
            <title>LVAD: Nesiritide</title>
            <description>Active arm of the LVAD group
randomized to receive nesiritide</description>
          </group>
          <group group_id="O4">
            <title>LVAD: Placebo</title>
            <description>Active arm of the LVAD group
randomized to receive placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate</title>
          <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Plasma Flow</title>
        <time_frame>46 Hours</time_frame>
        <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
        <group_list>
          <group group_id="O1">
            <title>Total Artificial Heart</title>
            <description>Nesiritide
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Total Artificial Heart: Placebo</title>
            <description>Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo</description>
          </group>
          <group group_id="O3">
            <title>LVAD: Nesiritide</title>
            <description>Active arm of the LVAD group
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O4">
            <title>LVAD: Placebo</title>
            <description>Control arm for subjects receiving LVAD and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Plasma Flow</title>
          <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Hemodialysis/Renal Replacement Therapy</title>
        <time_frame>90 days</time_frame>
        <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
        <group_list>
          <group group_id="O1">
            <title>Total Artificial Heart</title>
            <description>Nesiritide
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Total Artificial Heart: Placebo</title>
            <description>Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo</description>
          </group>
          <group group_id="O3">
            <title>LVAD: Nesiritide</title>
            <description>Active arm of the LVAD group
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O4">
            <title>LVAD: Placebo</title>
            <description>Control arm for subjects receiving LVAD and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Hemodialysis/Renal Replacement Therapy</title>
          <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urine Output</title>
        <time_frame>46 Hours</time_frame>
        <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
        <group_list>
          <group group_id="O1">
            <title>Total Artificial Heart</title>
            <description>Nesiritide
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Total Artificial Heart: Placebo</title>
            <description>Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo</description>
          </group>
          <group group_id="O3">
            <title>LVAD: Nesiritide</title>
            <description>Active arm of the LVAD group
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O4">
            <title>LVAD: Placebo</title>
            <description>Control arm for subjects receiving LVAD and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Urine Output</title>
          <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Renal Failure</title>
        <time_frame>46 Hours</time_frame>
        <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
        <group_list>
          <group group_id="O1">
            <title>Total Artificial Heart</title>
            <description>Nesiritide
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Total Artificial Heart: Placebo</title>
            <description>Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo</description>
          </group>
          <group group_id="O3">
            <title>LVAD: Nesiritide</title>
            <description>Active arm of the LVAD group
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O4">
            <title>LVAD: Placebo</title>
            <description>Control arm for subjects receiving LVAD and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Renal Failure</title>
          <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Diuretic Requirement</title>
        <time_frame>46 Hours</time_frame>
        <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
        <group_list>
          <group group_id="O1">
            <title>Total Artificial Heart</title>
            <description>Nesiritide
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Total Artificial Heart: Placebo</title>
            <description>Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo</description>
          </group>
          <group group_id="O3">
            <title>LVAD: Nesiritide</title>
            <description>Active arm of the LVAD group
nesiritide: nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.</description>
          </group>
          <group group_id="O4">
            <title>LVAD: Placebo</title>
            <description>Control arm for subjects receiving LVAD and randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Diuretic Requirement</title>
          <population>Analysis not done as study was closed early due to futility of reaching enrollment goals in the Total Artificial Heart arm</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No unexpected serious adverse events or adverse events were observed</desc>
      <group_list>
        <group group_id="E1">
          <title>Total Artificial Heart</title>
          <description>Active arm of the Total Artificial Heart group
randomized to receive nesiritide 0.005 mcg/kg/min without bolus</description>
        </group>
        <group group_id="E2">
          <title>Total Artificial Heart: Placebo</title>
          <description>Control arm of the Total Artificial Heart group
randomized to receive placebo</description>
        </group>
        <group group_id="E3">
          <title>LVAD: Nesiritide</title>
          <description>Active arm of the LVAD group
randomized to receive nesiritide at 0.005 mcg/kg/min without a bolus</description>
        </group>
        <group group_id="E4">
          <title>LVAD: Placebo</title>
          <description>Control arm of the LVAD group
randomized to receive placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Enrollment closed. Total Artificial Hearts (TAH) are rarely done as advances with Left Ventricular Assist Devices have improved. We were unable to meet enrollment goal based on the funding timeline due to the lack of TAH's for comparison to LVAD.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Keyur Shah, MD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-4571</phone>
      <email>kshah@mcvh-vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

